The global inflammatory bowel disease (IBD) industry is expected to grow at a CAGR of 4.5% from 2021 to 2030. The market is driven by the increasing prevalence of IBD, which is attributed to the rise in incidence of autoimmune diseases and lifestyle changes such as unhealthy diet and sedentary lifestyle. The North American region dominates the global IBD market due to its high prevalence rates, followed by Europe and Asia Pacific.
Some Of The Growth Factors Of This Market:
- The Inflammatory Bowel Disease Industry is expected to reach $5,814 million by 2022.
- Increasing prevalence of IBD in the US and Europe.
- Increasing awareness about IBD.
- Rising incidence of Crohn's disease and ulcerative colitis.
Industry Growth Insights published a new data on “Inflammatory Bowel Disease Industry Market”. The research report is titled “Inflammatory Bowel Disease Industry Market research by Types (5-ASA, Antibiotics, Immunomodulators, Other), By Applications (Hospital, Clinic, Other), By Players/Companies Pfizer, Abbvie, Merck, Abbott Laboratories, Biogen Idec, Janssen Pharmaceuticals, Merck & Company, Mitsubishi Tanabe, Salix Pharmaceuticals, Genentech, Shire, UCB, Akebia Therapeutics, Amgen, ChemoCentryx, Novartis, Boehringer Ingelheim, Celltrion, Novo Nordisk, Ferring Pharmaceuticals, Galapagos”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Inflammatory Bowel Disease Industry Market Research Report
By Type
5-ASA, Antibiotics, Immunomodulators, Other
By Application
Hospital, Clinic, Other
By Companies
Pfizer, Abbvie, Merck, Abbott Laboratories, Biogen Idec, Janssen Pharmaceuticals, Merck & Company, Mitsubishi Tanabe, Salix Pharmaceuticals, Genentech, Shire, UCB, Akebia Therapeutics, Amgen, ChemoCentryx, Novartis, Boehringer Ingelheim, Celltrion, Novo Nordisk, Ferring Pharmaceuticals, Galapagos
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Inflammatory Bowel Disease Industry Market Report Segments:
The global Inflammatory Bowel Disease Industry market is segmented on the basis of:
Types
5-ASA, Antibiotics, Immunomodulators, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Abbvie
- Merck
- Abbott Laboratories
- Biogen Idec
- Janssen Pharmaceuticals
- Merck & Company
- Mitsubishi Tanabe
- Salix Pharmaceuticals
- Genentech
- Shire
- UCB
- Akebia Therapeutics
- Amgen
- ChemoCentryx
- Novartis
- Boehringer Ingelheim
- Celltrion
- Novo Nordisk
- Ferring Pharmaceuticals
- Galapagos
Highlights of The Inflammatory Bowel Disease Industry Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5-ASA
- Antibiotics
- Immunomodulators
- Other
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Inflammatory Bowel Disease Industry Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The inflammatory bowel disease (IBD) industry is a $10.5 billion global market, with annual growth of 7%. IBD includes Crohn's disease and ulcerative colitis. The main drivers of the IBD industry are increasing incidence rates, growing awareness about the condition, and advances in treatments.
Some of the key players operating in the inflammatory bowel disease industry market are Pfizer, Abbvie, Merck, Abbott Laboratories, Biogen Idec, Janssen Pharmaceuticals, Merck & Company, Mitsubishi Tanabe, Salix Pharmaceuticals, Genentech, Shire, UCB, Akebia Therapeutics, Amgen, ChemoCentryx, Novartis, Boehringer Ingelheim, Celltrion, Novo Nordisk, Ferring Pharmaceuticals, Galapagos.
The inflammatory bowel disease industry market is expected to grow at a compound annual growth rate of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Inflammatory Bowel Disease Industry Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Inflammatory Bowel Disease Industry Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Inflammatory Bowel Disease Industry Market - Supply Chain
4.5. Global Inflammatory Bowel Disease Industry Market Forecast
4.5.1. Inflammatory Bowel Disease Industry Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Inflammatory Bowel Disease Industry Market Size (000 Units) and Y-o-Y Growth
4.5.3. Inflammatory Bowel Disease Industry Market Absolute $ Opportunity
5. Global Inflammatory Bowel Disease Industry Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Type
5.3.1. 5-ASA
5.3.2. Antibiotics
5.3.3. Immunomodulators
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Inflammatory Bowel Disease Industry Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Inflammatory Bowel Disease Industry Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Inflammatory Bowel Disease Industry Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Inflammatory Bowel Disease Industry Demand Share Forecast, 2019-2026
9. North America Inflammatory Bowel Disease Industry Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Type
9.7.1. 5-ASA
9.7.2. Antibiotics
9.7.3. Immunomodulators
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Inflammatory Bowel Disease Industry Demand Share Forecast, 2019-2026
10. Latin America Inflammatory Bowel Disease Industry Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Type
10.7.1. 5-ASA
10.7.2. Antibiotics
10.7.3. Immunomodulators
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Inflammatory Bowel Disease Industry Demand Share Forecast, 2019-2026
11. Europe Inflammatory Bowel Disease Industry Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Type
11.7.1. 5-ASA
11.7.2. Antibiotics
11.7.3. Immunomodulators
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Inflammatory Bowel Disease Industry Demand Share, 2019-2026
12. Asia Pacific Inflammatory Bowel Disease Industry Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Type
12.7.1. 5-ASA
12.7.2. Antibiotics
12.7.3. Immunomodulators
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Inflammatory Bowel Disease Industry Demand Share, 2019-2026
13. Middle East & Africa Inflammatory Bowel Disease Industry Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Inflammatory Bowel Disease Industry Market Size and Volume Forecast by Type
13.7.1. 5-ASA
13.7.2. Antibiotics
13.7.3. Immunomodulators
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Inflammatory Bowel Disease Industry Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Inflammatory Bowel Disease Industry Market: Market Share Analysis
14.2. Inflammatory Bowel Disease Industry Distributors and Customers
14.3. Inflammatory Bowel Disease Industry Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Abbvie
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Abbott Laboratories
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Biogen Idec
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Janssen Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck & Company
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mitsubishi Tanabe
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Salix Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Genentech
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Shire
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. UCB
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Akebia Therapeutics
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Amgen
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. ChemoCentryx
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Novartis
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Boehringer Ingelheim
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Celltrion
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Novo Nordisk
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Ferring Pharmaceuticals
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook